Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia.

Article Details

Citation

Copy to clipboard

Lowe FC

Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia.

Rev Urol. 2005;7 Suppl 4:S13-21.

PubMed ID

16986050 [ View in PubMed

]

Abstract

Tamsulosin, a uroselective alpha(1A)-adrenergic-receptor antagonist, has been shown to improve lower urinary tract symptoms associated with benign prostatic hyperplasia. It has a better side effect profile than earlier alpha-adrenergic-receptor antagonists, which were initially developed as antihypertensive agents. Clinical trials of 1 year or longer with tamsulosin show high tolerability for the 0.4 mg dose and no significant interaction with other antihypertensive medications.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tamsulosin	Alpha-1D adrenergic receptor	Protein	Humans	Unknown	Antagonist	Details